TOINV ... thank you for the kind words, it's mutual. As frustrating and disappointing as this RVX experience has been, I'm in too deep to cut & run. Haven't even really considered it to be honest. The science and safety just seems too good, and I don't want to be the 5th Beatle when it eventually comes to fruition, sameday, somehow. I am usually buying rather than selling, but stable and holding for now. I still see this as a home run stock at some point, and unlike many other ventures and going concerns, this probably isn't going to be an obvious progression ... news will likely come like a bolt of lightning (either good or bad), at some point. And if not a home run, I am still good with a double or triple, eventually.

BoM was a very narrow miss, with some known and significant bogeys attached to that trial. We were actually close to celebrating back then, with a flawed trial. BoM2 should have a lot better results, if/when it occurs. Personally, I hope BoM2 occurs under different management, after a buy out, if there is a BP out there that confidently sees this also, and can meet the BoD and investors at a mutually reasonable and happy median. Not getting any younger over here lol, sooner would be better for me, even at a discount (Warren Buffet mentality, take the profit and the win and move on).

Plus, and maybe more importantly overall, this ABL therapeutic needs to be available for the sick. It amazes me sometimes, that this gets lost amid the money discussions and drive. There should be an all out effort to get this through trials and to market, surprisingly that is not the case, seemingly.

Dreaming from the caboose.

glta